Discover
CNTA
Centessa Pharmaceuticals plc
40.50
1 x 29.07
1 x 51.57
bid
ask
+
0.00
0.00%
1 @ 04:00 PM
40.68 +0.18 (0.45%)
| Ytd | 61.94% | |
| 1y | 208.45% |
40.00
day range
40.56
13.20
52 week range
40.56
| Open | 40.09 | Prev Close | 40.50 | Low | 40.00 | High | 40.56 | Mkt Cap | 6.27B |
| Vol | 11.27M | Avg Vol | 1.93M | EPS | -1.78 | P/E | N/A | Forward P/E | -22.75 |
| Beta | 1.12 | Short Ratio | 1.35 | Inst. Own | 96.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 39.77 | 200-d Avg | 29.97 | 1yr Est | 40.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-03 | 0 | N/A | -0.14 | -36.84% |
| 2026-03-31 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-05 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-11-05 | 2025-09 | 0 | N/A | -0.02 | -5.13% |
| 2025-08-12 | 2025-06 | 0 | N/A | N/A | N/A |
| 2025-08-12 | 2025-06 | 0 | N/A | -0.03 | -8.57% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-20 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2026-04-02 | Guggenheim | Downgrade | Buy | Neutral |
| 2026-04-01 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2026-03-31 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| 2026-03-31 | Needham | Downgrade | Buy | Hold |
| 2026-02-24 | Wolfe Research | Upgrade | Outperform |
Profile
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-01 | ACCARDI MARIO ALBERTO | Chief Executive Officer | 243.89K | Stock Award(Grant) |
| 2026-03-25 | ANDERSON KAREN M | Officer | 62.09K | Sale |
| 2026-02-01 | BUSH TIA L | Chief Technology Officer | 147.95K | Stock Award(Grant) |
| 2025-03-16 | CHAO DAVID M | Officer | 225.01K | Sale |
| 2026-02-01 | CROWLEY JOHN JOSEPH CPA | Chief Financial Officer | 45.00K | Stock Award(Grant) |
| 2025-05-15 | GOYAL ARJUN | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Medicxi Ventures Management (Jersey) Ltd | 19.96M | 808.51M | 12.90% |
| 2026-03-30 | Avoro Capital Advisors LLC | 11.43M | 462.93M | 7.39% |
| 2026-03-30 | Index Venture Life Associates VI Ltd | 9.96M | 403.45M | 6.44% |
| 2026-03-30 | Adage Capital Partners GP L.L.C. | 8.93M | 361.46M | 5.77% |
| 2026-03-30 | Pentwater Capital Management Lp | 8.17M | 330.89M | 5.28% |
| 2026-03-30 | FMR, LLC | 6.85M | 277.51M | 4.43% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SmallCap World Fund Inc | 4.42M | 179.11M | 2.86% |
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 1.37M | 55.39M | 0.88% |
| 2026-04-29 | Fidelity Contrafund | 1.32M | 53.51M | 0.85% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 1.24M | 50.06M | 0.80% |
| 2026-04-29 | Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 787.00K | 31.87M | 0.51% |
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 668.14K | 27.06M | 0.43% |
Dividend
| Dividend | Date |
|---|---|
| 38 | 2026-06-24 |